A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Ocrelizumab in Participants With Relapsing Multiple Sclerosis and Primary Progressive Multiple Sclerosis

StatusActive, Not Recruiting
PhasePhase 4
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary endpoints: details revised at 1 of 3 entries
    • Eligibility criteria expanded, about 15 words
    • Secondary endpoints: details revised at 6 of 18 entries
    • Site details revised at 1 of 17 sites
  2. Primary completion pushed from Mar 12, 2027 to Dec 31, 2027
    • Trial status changed: Recruiting → Active, Not Recruiting
    • Study completion pushed from Apr 23, 2027 to Dec 31, 2028
    • Site details revised at 17 of 17 sites
    v4
  3. Re-verified, no change to tracked fieldsv3
  4. Site details revised at 1 of 17 sitesv2
  5. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The main purpose of this study is to evaluate the efficacy of ocrelizumab in participants with relapsing multiple sclerosis (RMS) and to characterize the ocrelizumab pharmacodynamic (PD) profile in Chinese participants with primary progressive multiple sclerosis (PPMS).
Trial Details
NCT Number NCT07483450
Lead Sponsor Hoffmann-La Roche
Conditions
(from sponsor)		 Relapsing Multiple Sclerosis, Primary Progressive Multiple Sclerosis
Related terms Multiple Sclerosis, Chronic Progressive
Enrollment 60 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov